Fintel reports that on December 2, 2025, HC Wainwright & Co. maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a Buy recommendation.
Analyst Price Forecast Suggests 10.17% Downside
As of November 17, 2025, the average one-year price target for Arrowhead Pharmaceuticals is $50.53/share. The forecasts range from a low of $17.17 to a high of $84.00. The average price target represents a decrease of 10.17% from its latest reported closing price of $56.25 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arrowhead Pharmaceuticals is 410MM, a decrease of 50.51%. The projected annual non-GAAP EPS is -1.33.
What is the Fund Sentiment?
There are 546 funds or institutions reporting positions in Arrowhead Pharmaceuticals. This is an increase of 25 owner(s) or 4.80% in the last quarter. Average portfolio weight of all funds dedicated to ARWR is 0.14%, an increase of 37.36%. Total shares owned by institutions increased in the last three months by 4.57% to 130,072K shares. 
The put/call ratio of ARWR is 0.32, indicating a bullish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 10,900K shares representing 8.03% ownership of the company. In its prior filing, the firm reported owning 10,600K shares , representing an increase of 2.75%. The firm increased its portfolio allocation in ARWR by 65.68% over the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 7,520K shares representing 5.54% ownership of the company. In its prior filing, the firm reported owning 7,840K shares , representing a decrease of 4.26%. The firm increased its portfolio allocation in ARWR by 17.94% over the last quarter.
Slate Path Capital holds 4,982K shares representing 3.67% ownership of the company. In its prior filing, the firm reported owning 5,232K shares , representing a decrease of 5.02%. The firm increased its portfolio allocation in ARWR by 86.54% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,872K shares representing 2.85% ownership of the company. In its prior filing, the firm reported owning 3,399K shares , representing an increase of 12.20%. The firm increased its portfolio allocation in ARWR by 26.03% over the last quarter.
Geode Capital Management holds 3,131K shares representing 2.31% ownership of the company. In its prior filing, the firm reported owning 2,979K shares , representing an increase of 4.87%. The firm increased its portfolio allocation in ARWR by 10.94% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
